CTOs on the Move

MEDISCA

www.medisca.com

 
With over 25 years of experience, MEDISCA has developed a solid reputation as an innovative and entrepreneurial company in the pharmaceutical compounding industry.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.medisca.com
  • 6090 Henri-Bourassa Blvd W
    Saint-Laurent, QC CAN H4R 3A6
  • Phone: 514.333.7811

Executives

Name Title Contact Details

Similar Companies

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of ...

TerrAscend

TerrAscend provides quality products, brands, and services to the global cannabinoid market. As the first North American Operator (NAO), with scale operations in both Canada and the US, TerrAscend participates in the medical and legal adult-use market across Canada and in several US states where cannabis has been legalized for therapeutic or adult use. TerrAscend was the first cannabis company with sales in the US, Canada, and Europe. TerrAscend operates a number of synergistic businesses, including The Apothecarium, an award-winning cannabis dispensary with retail locations in California and Pennsylvania; Arise Bioscience Inc., a manufacturer, and distributor of hemp-derived products; Ilera Healthcare, Pennsylvania`s premier medical cannabis cultivator, processor and dispenser; State Flower, an ultra premium cannabis brand focused on the cultivation of truly exceptional flowers; and Valhalla Confections, a manufacturer of premium cannabis-infused edibles. TerrAscend holds a cultivation permit in the State of New Jersey and is pending approval for a vertically integrated medical cannabis operation with the ability to operate up to 3 Alternative Treatment Centers. Additionally, TerrAscend holds a Medical Cannabis Processor License in the State of Utah.

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.

PharmaMed Resources

PharmaMed Resources is a Kenilworth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immuno Vaccine

Immuno Vaccine is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.